Suppr超能文献

肝移植时的时间作为肝移植后肝细胞癌复发的预测指标。

Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.

作者信息

Samoylova Mariya L, Dodge Jennifer L, Yao Francis Y, Roberts John Paul

机构信息

Departments of Surgery (Division of Transplant Surgery), University of California San Francisco, San Francisco, CA.

出版信息

Liver Transpl. 2014 Aug;20(8):937-44. doi: 10.1002/lt.23902. Epub 2014 Jul 3.

Abstract

In the United States, there are significant geographic disparities in the time to transplantation for patients with hepatocellular carcinoma (HCC); it is possible that rapid transplantation contributes to higher rates of posttransplant HCC recurrence because there is insufficient time for the tumor biology to manifest. In this study, we compared HCC recurrence in rapid transplant patients and their slower transplant counterparts. We identified adult liver transplantation (LT) candidates in the Organ Procurement and Transplantation Network/United Network for Organ Sharing (UNOS) data set who were granted an initial exception for an HCC diagnosis between January 1, 2006 and September 30, 2010 and underwent transplantation in the same time window. Patients were followed until HCC recurrence, non-HCC-related death, or last follow-up. The cumulative incidence of HCC recurrence was compared for patients waiting ≤ 120 days and patients waiting >120 days from an HCC exception to LT. The association between the risk of posttransplant recurrence and the wait time was further evaluated via competing risks regression with the Fine and Gray model. For 5002 LT recipients with HCC, the median wait time from an exception to LT was 77 days, and it varied from 30 to 169 days by UNOS region. The cumulative incidence of posttransplant HCC recurrence was 3.3% [95% confidence interval (CI) = 2.8%-3.8%] and 5.6% (95% CI = 5.0%-6.3%) within 1 and 2 years, respectively. The rate of observed recurrence within 1 year of transplantation was significantly lower for patients waiting >120 days versus patients waiting ≤ 120 days (2.2% versus 3.9%, P = 0.002); however, the difference did not persist at 2 years (5.0% versus 5.9%, P = 0.09). After we accounted for clinical factors, the HCC recurrence risk was reduced by 40% for patients waiting >120 days (subhazard ratio = 0.6, P = 0.005). In conclusion, the risk of HCC recurrence within the first year after transplantation may be lessened by the institution of a mandatory waiting time after an exception is granted.

摘要

在美国,肝细胞癌(HCC)患者接受移植的时间存在显著的地域差异;快速移植可能导致移植后HCC复发率较高,因为肿瘤生物学特性没有足够时间显现出来。在本研究中,我们比较了快速移植患者和移植较慢患者的HCC复发情况。我们在器官获取与移植网络/器官共享联合网络(UNOS)数据集中确定了成年肝移植(LT)候选人,这些人在2006年1月1日至2010年9月30日期间因HCC诊断获得了初始豁免,并在同一时间窗口内接受了移植。对患者进行随访,直至HCC复发、非HCC相关死亡或最后一次随访。比较了从HCC豁免到LT等待≤120天的患者和等待>120天的患者HCC复发的累积发生率。通过使用Fine和Gray模型的竞争风险回归进一步评估移植后复发风险与等待时间之间的关联。对于5002例接受LT的HCC患者,从豁免到LT的中位等待时间为77天,按UNOS地区不同,从30天到169天不等。移植后1年和2年内HCC复发的累积发生率分别为3.3%[95%置信区间(CI)=2.8%-3.8%]和5.6%(95%CI=5.0%-6.3%)。移植后1年内,等待>120天的患者观察到的复发率显著低于等待≤120天的患者(2.2%对3.9%,P=0.002);然而,2年时差异不再存在(5.0%对5.9%,P=0.09)。在我们考虑了临床因素后,等待>120天的患者HCC复发风险降低了40%(亚风险比=0.6,P=0.005)。总之,在获得豁免后设定强制等待时间,可能会降低移植后第一年HCC复发的风险。

相似文献

1
Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.
Liver Transpl. 2014 Aug;20(8):937-44. doi: 10.1002/lt.23902. Epub 2014 Jul 3.
3
Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database.
Liver Transpl. 2013 Dec;19(12):1318-23. doi: 10.1002/lt.23735. Epub 2013 Oct 21.
4
Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Transplantation. 2024 May 1;108(5):1172-1178. doi: 10.1097/TP.0000000000004860. Epub 2023 Nov 13.

引用本文的文献

1
Hepatocellular Carcinoma and the Role of Liver Transplantation: An Update and Review.
J Clin Transl Hepatol. 2025 Apr 28;13(4):327-338. doi: 10.14218/JCTH.2024.00432. Epub 2025 Feb 24.
2
Predicting waitlist dropout in hepatocellular carcinoma: a narrative review.
Transl Gastroenterol Hepatol. 2024 Aug 21;9:72. doi: 10.21037/tgh-24-24. eCollection 2024.
7
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review.
Clin Mol Hepatol. 2022 Oct;28(4):739-753. doi: 10.3350/cmh.2022.0060. Epub 2022 Apr 26.
9
Liver Living Donation for Cancer Patients: Benefits, Risks, Justification.
Recent Results Cancer Res. 2021;218:135-148. doi: 10.1007/978-3-030-63749-1_10.
10
Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy.
J Clin Transl Hepatol. 2021 Apr 28;9(2):220-226. doi: 10.14218/JCTH.2020.00037. Epub 2021 Mar 22.

本文引用的文献

2
Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database.
Liver Transpl. 2013 Dec;19(12):1318-23. doi: 10.1002/lt.23735. Epub 2013 Oct 21.
6
Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis.
Clin Transplant. 2013 Jan-Feb;27(1):140-7. doi: 10.1111/ctr.12031. Epub 2012 Nov 15.
8
Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
Clin Transplant. 2012 Jul-Aug;26(4):E359-64. doi: 10.1111/j.1399-0012.2012.01668.x. Epub 2012 Jun 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验